Patents by Inventor Daniel J. Powell

Daniel J. Powell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190125797
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Application
    Filed: October 1, 2018
    Publication date: May 2, 2019
    Inventors: Daniel J. Powell, JR., Carl H. June
  • Patent number: 10273300
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 30, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Patent number: 10266580
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 23, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
  • Patent number: 10259849
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 16, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Patent number: 10233425
    Abstract: The invention includes compositions and methods to rapidly isolate and culture cells that are potent for use in adoptive immunotherapy. In one embodiment, the isolated cells of the invention are tumor infiltrating lymphocytes (TIL) that express CD137 (also known as 4-1BB and TNFSFR9).
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: March 19, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Patent number: 10117896
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: November 6, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, Jr., Carl H. June
  • Publication number: 20180133296
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: April 15, 2016
    Publication date: May 17, 2018
    Inventors: David Maxwell Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • Publication number: 20180057557
    Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of FSHR. The invention provides novel peptides that specifically bind to Follicle-stimulation hormone receptor (FSHR).
    Type: Application
    Filed: November 3, 2015
    Publication date: March 1, 2018
    Inventors: Daniel J. Powell, Jr., Caitlin Stashwick, Katarzyna Urbanska
  • Publication number: 20180044424
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Application
    Filed: February 1, 2016
    Publication date: February 15, 2018
    Inventors: Carl H. June, Daniel J. Powell, Jr.
  • Publication number: 20180030110
    Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 1, 2018
    Inventor: Daniel J. Powell, Jr.
  • Publication number: 20170342124
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Application
    Filed: May 10, 2017
    Publication date: November 30, 2017
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
  • Publication number: 20170335281
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
    Type: Application
    Filed: March 13, 2015
    Publication date: November 23, 2017
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Andreas Loew, Michael C. Milone, Daniel J. Powell, Jr., Yangbing Zhao
  • Publication number: 20170240630
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.
    Type: Application
    Filed: March 3, 2017
    Publication date: August 24, 2017
    Inventor: Daniel J. Powell, Jr.
  • Patent number: 9708384
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: July 18, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
  • Publication number: 20170151283
    Abstract: The invention provides compositions and methods for overcoming poor response to antibody therapy, for example, antibody resistance. The invention also relates to at least one immune receptor (IR) specific to the Fc receptor, vectors comprising the same, and recombinant T cells comprising the Fc immune receptor. The invention also includes methods of administering a modified T cell expressing an immune receptor that comprises a Fc binding domain.
    Type: Application
    Filed: May 22, 2015
    Publication date: June 1, 2017
    Inventor: Daniel J. POWELL
  • Publication number: 20170137783
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: July 21, 2016
    Publication date: May 18, 2017
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, JR., Zoe Zheng
  • Patent number: 9598489
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having alpha-folate receptor (FR-alpha) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR-alpha binding domain is fully human, thereby preventing a host immune response.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: March 21, 2017
    Assignee: The Trustees of the Univeristy of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Publication number: 20170002072
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 5, 2017
    Inventors: Daniel J. Powell, George Coukos
  • Patent number: 9446105
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML). The invention also relates to at least one chimeric antigen receptor (CAR) specific to folate receptor beta (FR?), vectors comprising the same, and recombinant T cells comprising the FR? CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a FR? binding domain in combination with a RXR agonist, such as all-trans retinoic acid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Patent number: 9422351
    Abstract: The present invention relates to B7-H4-specific chimeric antigen receptor compositions and methods of use thereof.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: August 23, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell